Thus, DCs have to uptake tumor-derived materials and to process it into epitopes that will then not only be cross-presented on their HLA class I molecules in order to prime CD8+ T cells but also reach the HLA class II-processing pathway for their presentation to CD4+ T helper cells that will further promote the functional interaction between DC and effector cells [2]. This evidence concerns the gene CD8A and neoplasm.